1
|
Châtre R, Blochouse E, Eid R, Djago F, Lange J, Tarighi M, Renoux B, Sobilo J, Le Pape A, Clarhaut J, Geffroy C, Opalinski I, Tuo W, Papot S, Poinot P. Induced-volatolomics for the design of tumour activated therapy. Chem Sci 2023; 14:4697-4703. [PMID: 37181780 PMCID: PMC10171039 DOI: 10.1039/d2sc06797h] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2022] [Accepted: 04/07/2023] [Indexed: 05/16/2023] Open
Abstract
The discovery of tumour-associated markers is of major interest for the development of selective cancer chemotherapy. Within this framework, we introduced the concept of induced-volatolomics enabling to monitor simultaneously the dysregulation of several tumour-associated enzymes in living mice or biopsies. This approach relies on the use of a cocktail of volatile organic compound (VOC)-based probes that are activated enzymatically for releasing the corresponding VOCs. Exogenous VOCs can then be detected in the breath of mice or in the headspace above solid biopsies as specific tracers of enzyme activities. Our induced-volatolomics modality highlighted that the up-regulation of N-acetylglucosaminidase was a hallmark of several solid tumours. Having identified this glycosidase as a potential target for cancer therapy, we designed an enzyme-responsive albumin-binding prodrug of the potent monomethyl auristatin E programmed for the selective release of the drug in the tumour microenvironment. This tumour activated therapy produced a remarkable therapeutic efficacy on orthotopic triple-negative mammary xenografts in mice, leading to the disappearance of tumours in 66% of treated animals. Thus, this study shows the potential of induced-volatolomics for the exploration of biological processes as well as the discovery of novel therapeutic strategies.
Collapse
Affiliation(s)
- Rémi Châtre
- University of Poitiers, UMR CNRS 7285, Institut de Chimie des Milieux et Matériaux de Poitiers (IC2MP), Equipe Labellisée Ligue Contre le Cancer 4 Rue Michel-Brunet, TSA 51106 86073 Poitiers Cedex 9 France
| | - Estelle Blochouse
- University of Poitiers, UMR CNRS 7285, Institut de Chimie des Milieux et Matériaux de Poitiers (IC2MP), Equipe Labellisée Ligue Contre le Cancer 4 Rue Michel-Brunet, TSA 51106 86073 Poitiers Cedex 9 France
| | - Rony Eid
- University of Poitiers, UMR CNRS 7285, Institut de Chimie des Milieux et Matériaux de Poitiers (IC2MP), Equipe Labellisée Ligue Contre le Cancer 4 Rue Michel-Brunet, TSA 51106 86073 Poitiers Cedex 9 France
| | - Fabiola Djago
- University of Poitiers, UMR CNRS 7285, Institut de Chimie des Milieux et Matériaux de Poitiers (IC2MP), Equipe Labellisée Ligue Contre le Cancer 4 Rue Michel-Brunet, TSA 51106 86073 Poitiers Cedex 9 France
| | - Justin Lange
- University of Poitiers, UMR CNRS 7285, Institut de Chimie des Milieux et Matériaux de Poitiers (IC2MP), Equipe Labellisée Ligue Contre le Cancer 4 Rue Michel-Brunet, TSA 51106 86073 Poitiers Cedex 9 France
| | - Mehrad Tarighi
- University of Poitiers, UMR CNRS 7285, Institut de Chimie des Milieux et Matériaux de Poitiers (IC2MP), Equipe Labellisée Ligue Contre le Cancer 4 Rue Michel-Brunet, TSA 51106 86073 Poitiers Cedex 9 France
| | - Brigitte Renoux
- University of Poitiers, UMR CNRS 7285, Institut de Chimie des Milieux et Matériaux de Poitiers (IC2MP), Equipe Labellisée Ligue Contre le Cancer 4 Rue Michel-Brunet, TSA 51106 86073 Poitiers Cedex 9 France
| | - Julien Sobilo
- UAR No. 44 PHENOMIN TAAM-Imagerie In Vivo, CNRS 3B Rue de la Férollerie F-45071 Orléans France
| | - Alain Le Pape
- UAR No. 44 PHENOMIN TAAM-Imagerie In Vivo, CNRS 3B Rue de la Férollerie F-45071 Orléans France
| | - Jonathan Clarhaut
- University of Poitiers, UMR CNRS 7285, Institut de Chimie des Milieux et Matériaux de Poitiers (IC2MP), Equipe Labellisée Ligue Contre le Cancer 4 Rue Michel-Brunet, TSA 51106 86073 Poitiers Cedex 9 France
- CHU de Poitiers 2 Rue de la Miléterie, CS 90577 F-86021 Poitiers France
| | - Claude Geffroy
- University of Poitiers, UMR CNRS 7285, Institut de Chimie des Milieux et Matériaux de Poitiers (IC2MP), Equipe Labellisée Ligue Contre le Cancer 4 Rue Michel-Brunet, TSA 51106 86073 Poitiers Cedex 9 France
| | - Isabelle Opalinski
- University of Poitiers, UMR CNRS 7285, Institut de Chimie des Milieux et Matériaux de Poitiers (IC2MP), Equipe Labellisée Ligue Contre le Cancer 4 Rue Michel-Brunet, TSA 51106 86073 Poitiers Cedex 9 France
| | - Wei Tuo
- University of Poitiers, UMR CNRS 7285, Institut de Chimie des Milieux et Matériaux de Poitiers (IC2MP), Equipe Labellisée Ligue Contre le Cancer 4 Rue Michel-Brunet, TSA 51106 86073 Poitiers Cedex 9 France
| | - Sébastien Papot
- University of Poitiers, UMR CNRS 7285, Institut de Chimie des Milieux et Matériaux de Poitiers (IC2MP), Equipe Labellisée Ligue Contre le Cancer 4 Rue Michel-Brunet, TSA 51106 86073 Poitiers Cedex 9 France
- Seekyo SA 2 Avenue Galilée, BP 30153 86961 Futuroscope France
| | - Pauline Poinot
- University of Poitiers, UMR CNRS 7285, Institut de Chimie des Milieux et Matériaux de Poitiers (IC2MP), Equipe Labellisée Ligue Contre le Cancer 4 Rue Michel-Brunet, TSA 51106 86073 Poitiers Cedex 9 France
| |
Collapse
|
2
|
Nguyen PV, Allard-Vannier E, Aubrey N, Labrugère-Sarroste C, Chourpa I, Sobilo J, Le Pape A, Hervé-Aubert K. Radiolabeling, Quality Control and In Vivo Imaging of Multimodal Targeted Nanomedicines. Pharmaceutics 2022; 14:pharmaceutics14122679. [PMID: 36559172 PMCID: PMC9784797 DOI: 10.3390/pharmaceutics14122679] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2022] [Revised: 11/24/2022] [Accepted: 11/24/2022] [Indexed: 12/05/2022] Open
Abstract
Following our previous study on the development of EGFR-targeted nanomedicine (NM-scFv) for the active delivery of siRNA in EGFR-positive cancers, this study focuses on the development and the quality control of a radiolabeling method to track it in in vivo conditions with nuclear imaging. Our NM-scFv is based on the electrostatic complexation of targeted nanovector (NV-scFv), siRNA and two cationic polymers. NV-scFv comprises an inorganic core, a fluorescent dye, a polymer layer and anti-EGFR ligands. To track NM-scFv in vivo with nuclear imaging, the DTPA chemistry was used to radiolabel NM-scFv with 111In. DTPA was thiolated and introduced onto NV-scFv via the maleimide chemistry. To obtain suitable radiolabeling efficiency, different DTPA/NV-scFv ratios were tested, including 0.03, 0.3 and 0.6. At the optimized ratio (where the DTPA/NV-scFv ratio was 0.3), a high radiolabeling yield was achieved (98%) and neither DTPA-derivatization nor indium-radiolabeling showed any impact on NM-scFv’s physicochemical characteristics (DH ~100 nm, PDi < 0.24). The selected NM-scFv-DTPA demonstrated good siRNA protection capacity and comparable in vitro transfection efficiency into EGFR-overexpressing cells in comparison to that of non-derivatized NM-scFv (around 67%). Eventually, it was able to track both qualitatively and quantitatively NM-scFv in in vivo environments with nuclear imaging. Both the radiolabeling and the NM-scFv showed a high in vivo stability level. Altogether, a radiolabeling method using DTPA chemistry was developed with success in this study to track our NM-scFv in in vivo conditions without any impact on its active targeting and physicochemical properties, highlighting the potential of our NM-scFv for future theranostic applications in EGFR-overexpressing cancers.
Collapse
Affiliation(s)
- Phuoc-Vinh Nguyen
- EA6295 Nanomedicines and Nanoprobes, University of Tours, 37000 Tours, France
- School of Medicine, Vietnam National University Ho Chi Minh City, Ho Chi Minh City 700000, Vietnam
| | | | - Nicolas Aubrey
- ISP UMR 1282, INRA, BioMAP, University of Tours, 37000 Tours, France
| | | | - Igor Chourpa
- EA6295 Nanomedicines and Nanoprobes, University of Tours, 37000 Tours, France
| | | | | | - Katel Hervé-Aubert
- EA6295 Nanomedicines and Nanoprobes, University of Tours, 37000 Tours, France
- Correspondence:
| |
Collapse
|
3
|
Guéguinou M, Ibrahim S, Bourgeais J, Robert A, Pathak T, Zhang X, Crottès D, Dupuy J, Ternant D, Monbet V, Guibon R, Flores-Romero H, Lefèvre A, Lerondel S, Le Pape A, Dumas JF, Frank PG, Girault A, Chautard R, Guéraud F, García-Sáez AJ, Ouaissi M, Emond P, Sire O, Hérault O, Fromont-Hankard G, Vandier C, Tougeron D, Trebak M, Raoul W, Lecomte T. Curcumin and NCLX inhibitors share anti-tumoral mechanisms in microsatellite-instability-driven colorectal cancer. Cell Mol Life Sci 2022; 79:284. [PMID: 35526196 PMCID: PMC11072810 DOI: 10.1007/s00018-022-04311-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2022] [Revised: 04/05/2022] [Accepted: 04/15/2022] [Indexed: 11/03/2022]
Abstract
BACKGROUND AND AIMS Recent evidences highlight a role of the mitochondria calcium homeostasis in the development of colorectal cancer (CRC). To overcome treatment resistance, we aimed to evaluate the role of the mitochondrial sodium-calcium-lithium exchanger (NCLX) and its targeting in CRC. We also identified curcumin as a new inhibitor of NCLX. METHODS We examined whether curcumin and pharmacological compounds induced the inhibition of NCLX-mediated mitochondrial calcium (mtCa2+) extrusion, the role of redox metabolism in this process. We evaluated their anti-tumorigenic activity in vitro and in a xenograft mouse model. We analyzed NCLX expression and associations with survival in The Cancer Genome Atlas (TCGA) dataset and in tissue microarrays from 381 patients with microsatellite instability (MSI)-driven CRC. RESULTS In vitro, curcumin exerted strong anti-tumoral activity through its action on NCLX with mtCa2+ and reactive oxygen species overload associated with a mitochondrial membrane depolarization, leading to reduced ATP production and apoptosis. NCLX inhibition with pharmacological and molecular approaches reproduced the effects of curcumin. NCLX inhibitors decreased CRC tumor growth in vivo. Both transcriptomic analysis of TCGA dataset and immunohistochemical analysis of tissue microarrays demonstrated that higher NCLX expression was associated with MSI status, and for the first time, NCLX expression was significantly associated with recurrence-free survival. CONCLUSIONS Our findings highlight a novel anti-tumoral mechanism of curcumin through its action on NCLX and mitochondria calcium overload that could benefit for therapeutic schedule of patients with MSI CRC.
Collapse
Affiliation(s)
- Maxime Guéguinou
- EA 7501 GICC, Université de Tours, Tours, France.
- N2C, Nutrition Growth and Cancer, Faculté de Médecine, Université de Tours, Inserm, UMR 1069, Tours, France.
| | | | | | - Alison Robert
- N2C, Nutrition Growth and Cancer, Faculté de Médecine, Université de Tours, Inserm, UMR 1069, Tours, France
| | - Trayambak Pathak
- Department of Cellular and Molecular Physiology, College of Medicine, The Pennsylvania State University, 500 University Dr, Hershey, PA, 17033, USA
| | - Xuexin Zhang
- Department of Cellular and Molecular Physiology, College of Medicine, The Pennsylvania State University, 500 University Dr, Hershey, PA, 17033, USA
| | - David Crottès
- N2C, Nutrition Growth and Cancer, Faculté de Médecine, Université de Tours, Inserm, UMR 1069, Tours, France
| | - Jacques Dupuy
- TOXALIM (Research Centre in Food Toxicology)-Team E9-PPCA, Université de Toulouse, UMR 1331 INRAE, ENVT, INP-Purpan, UPS, Toulouse, France
| | - David Ternant
- EA 7501 GICC, Université de Tours, Tours, France
- EA4245 Transplant Immunology and Inflammation, Université de Tours, 10 Boulevard Tonnellé, 37032, Tours, France
| | - Valérie Monbet
- IRMAR Mathematics Research Institute of Rennes, UMR-CNRS 6625, Rennes, France
| | - Roseline Guibon
- N2C, Nutrition Growth and Cancer, Faculté de Médecine, Université de Tours, Inserm, UMR 1069, Tours, France
| | - Hector Flores-Romero
- Institute for Genetics, University of Cologne, Cologne, Germany
- Cologne Excellence Cluster On Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany
- Interfaculty Institute of Biochemistry, Eberhard-Karls-Universität Tübingen, Tübingen, Germany
| | - Antoine Lefèvre
- UMR 1253, iBrain, Université de Tours, Inserm, 37000, Tours, France
| | | | | | - Jean-François Dumas
- N2C, Nutrition Growth and Cancer, Faculté de Médecine, Université de Tours, Inserm, UMR 1069, Tours, France
| | - Philippe G Frank
- N2C, Nutrition Growth and Cancer, Faculté de Médecine, Université de Tours, Inserm, UMR 1069, Tours, France
| | - Alban Girault
- Laboratory of Cellular and Molecular Physiology, UR UPJV 4667, University of Picardie Jules Verne, Amiens, France
| | | | - Françoise Guéraud
- TOXALIM (Research Centre in Food Toxicology)-Team E9-PPCA, Université de Toulouse, UMR 1331 INRAE, ENVT, INP-Purpan, UPS, Toulouse, France
| | - Ana J García-Sáez
- Institute for Genetics, University of Cologne, Cologne, Germany
- Cologne Excellence Cluster On Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany
- Interfaculty Institute of Biochemistry, Eberhard-Karls-Universität Tübingen, Tübingen, Germany
| | - Mehdi Ouaissi
- EA4245 Transplant Immunology and Inflammation, Université de Tours, 10 Boulevard Tonnellé, 37032, Tours, France
| | - Patrick Emond
- UMR 1253, iBrain, Université de Tours, Inserm, 37000, Tours, France
| | - Olivier Sire
- IRDL Institut de Recherche Dupuy de Lôme, UMR-CNRS, 06027, Vannes, France
| | | | - Gaëlle Fromont-Hankard
- N2C, Nutrition Growth and Cancer, Faculté de Médecine, Université de Tours, Inserm, UMR 1069, Tours, France
| | - Christophe Vandier
- N2C, Nutrition Growth and Cancer, Faculté de Médecine, Université de Tours, Inserm, UMR 1069, Tours, France
| | - David Tougeron
- Hepato-Gastroenterology Department, Poitiers University Hospital and Faculty of Medicine of Poitiers, 86000, Poitiers, France
| | - Mohamed Trebak
- Department of Cellular and Molecular Physiology, College of Medicine, The Pennsylvania State University, 500 University Dr, Hershey, PA, 17033, USA
| | - William Raoul
- EA 7501 GICC, Université de Tours, Tours, France
- N2C, Nutrition Growth and Cancer, Faculté de Médecine, Université de Tours, Inserm, UMR 1069, Tours, France
| | - Thierry Lecomte
- EA 7501 GICC, Université de Tours, Tours, France.
- N2C, Nutrition Growth and Cancer, Faculté de Médecine, Université de Tours, Inserm, UMR 1069, Tours, France.
- Department of Hepato-Gastroenterology and Digestive Oncology, CHRU de Tours, Tours, France.
| |
Collapse
|
4
|
Chadet S, Allard J, Brisson L, Lopez-Charcas O, Lemoine R, Heraud A, Lerondel S, Guibon R, Fromont G, Le Pape A, Angoulvant D, Jiang LH, Murrell-Lagnado R, Roger S. P2x4 receptor promotes mammary cancer progression by sustaining autophagy and associated mesenchymal transition. Oncogene 2022; 41:2920-2931. [DOI: 10.1038/s41388-022-02297-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2021] [Revised: 03/18/2022] [Accepted: 03/24/2022] [Indexed: 12/22/2022]
|
5
|
Majoral C, Coates AL, Le Pape A, Vecellio L. Humidified and Heated Cascade Impactor for Aerosol Sizing. Front Bioeng Biotechnol 2020; 8:589782. [PMID: 33282850 PMCID: PMC7691492 DOI: 10.3389/fbioe.2020.589782] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2020] [Accepted: 10/22/2020] [Indexed: 11/21/2022] Open
Abstract
Aerosol sizing is generally measured at ambient air but human airways have different temperature (37°C) and relative humidity (100%) which can affect particle size in airways and consequently deposition prediction. This work aimed to develop and evaluate a new method using cascade impactor to measure particle size at human physiological temperature and humidity (HPTH) taking into account ambient air conditions. A heated and humidified trachea was built and a cascade impactor was heated to 37°C and humidified inside. Four medical aerosols [jet nebulizer, mesh nebulizer, Presurized Metered Dose Inhaler (pMDI), and Dry Powder Inhaler (DPI)] under ambient conditions and at HPTH were tested. MMAD was lower at HPTH for the two nebulizers; it was similar at ambient conditions and HPTH for pMDI, and the mass of particles smaller than 5 μm decreased for DPI at HPTH (51.9 vs. 82.8 μg/puff). In conclusion, we developed a new method to measure particle size at HPTH affecting deposition prediction with relevance. In vivo studies are required to evaluate the interest of this new model to improve the precision of deposition prediction.
Collapse
Affiliation(s)
- Caroline Majoral
- INSERM, Research Center for Respiratory Diseases, Tours, France.,Université de Tours, Tours, France
| | | | - Alain Le Pape
- INSERM, Research Center for Respiratory Diseases, Tours, France.,Université de Tours, Tours, France
| | - Laurent Vecellio
- INSERM, Research Center for Respiratory Diseases, Tours, France.,Université de Tours, Tours, France
| |
Collapse
|
6
|
Buggisch JR, Göhler D, Le Pape A, Roger S, Ouaissi M, Stintz M, Rudolph A, Giger-Pabst U. Experimental Model to Test Electrostatic Precipitation Technology in the COVID-19 Era: A Pilot Study. J Am Coll Surg 2020; 231:704-712. [PMID: 32891798 PMCID: PMC7470820 DOI: 10.1016/j.jamcollsurg.2020.08.759] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2020] [Revised: 08/20/2020] [Accepted: 08/21/2020] [Indexed: 12/16/2022]
Abstract
BACKGROUND In the COVID-19 crisis, laparoscopic surgery is in focus as a relevant source of bioaerosol release. The efficacy of electrostatic aerosol precipitation (EAP) and continuous aerosol evacuation (CAE) to eliminate bioaerosols during laparoscopic surgery was verified. STUDY DESIGN Ex-vivo laparoscopic cholecystectomies (LCs) were simulated ± EAP or CAE in Pelvitrainer equipped with swine gallbladders. Release of bioaerosols was initiated by performing high-frequency electrosurgery with a monopolar electro hook (MP-HOOK) force at 40 watts (MP-HOOK40) and 60 watts (MP-HOOK60), as well as by ultrasonic cutting (USC). Particle number concentrations (PNC) of arising aerosols were analyzed with a condensation particle counter (CPC). Aerosol samples were taken within the Pelvitrainer close to the source, outside the Pelvitrainer at the working trocar, and in the breathing zone of the surgeon. RESULTS Within the Pelvitrainer, MP-HOOK40 (6.4 × 105 cm-3) and MP-HOOK60 (7.3 × 105 cm-3) showed significantly higher median PNCs compared to USC (4.4 × 105 cm-3) (p = 0.001). EAP led to a significant decrease of the median PNCs in all 3 groups. A high linear correlation with Pearson correlation coefficients of 0.852, 0.825, and 0.759 were observed by comparing MP-HOOK40 (± EAP), MP-HOOK60 (± EAP), and USC (± EAP), respectively. During ex-vivo LC and CAE, significant bioaerosol contaminations of the operating room occurred. Ex-vivo LC with EAP led to a considerable reduction of the bioaerosol concentration. CONCLUSIONS EAP was found to be efficient for intraoperative bioaerosol elimination and reducing the risk of bioaerosol exposure for surgical staff.
Collapse
Affiliation(s)
| | - Daniel Göhler
- Technologie-orientierte Partikel-, Analysen- und Sensortechnik, Topas GmbH, Dresden, Germany
| | - Alain Le Pape
- CNRS UPS44, CIPA, PHENOMIN-TAAM, Orléans, Tours, France
| | - Sébastien Roger
- EA4245 Transplantation, Immunologie, Inflammation, Université de Tours, Tours, Tours, France; Institut Universitaire de France, Paris, Tours, France
| | - Mehdi Ouaissi
- EA4245 Transplantation, Immunologie, Inflammation, Université de Tours, Tours, Tours, France; Department of Digestive, Oncological, Endocrine, Hepato-Biliary, Pancreatic and Liver Transplant Surgery, University Hospital of Tours, Tours, France
| | - Michael Stintz
- Research Group Mechanical Process Engineering, Institute of Process Engineering and Environmental Technology, Technische Universität Dresden, Dresden, Germany
| | - Andreas Rudolph
- Technologie-orientierte Partikel-, Analysen- und Sensortechnik, Topas GmbH, Dresden, Germany
| | | |
Collapse
|
7
|
Brisson L, Chadet S, Lopez-Charcas O, Jelassi B, Ternant D, Chamouton J, Lerondel S, Le Pape A, Couillin I, Gombault A, Trovero F, Chevalier S, Besson P, Jiang LH, Roger S. P2X7 Receptor Promotes Mouse Mammary Cancer Cell Invasiveness and Tumour Progression, and Is a Target for Anticancer Treatment. Cancers (Basel) 2020; 12:cancers12092342. [PMID: 32825056 PMCID: PMC7565976 DOI: 10.3390/cancers12092342] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2020] [Revised: 08/12/2020] [Accepted: 08/17/2020] [Indexed: 12/20/2022] Open
Abstract
The P2X7 receptor is an ATP-gated cation channel with a still ambiguous role in cancer progression, proposed to be either pro- or anti-cancerous, depending on the cancer or cell type in the tumour. Its role in mammary cancer progression is not yet defined. Here, we show that P2X7 receptor is functional in highly aggressive mammary cancer cells, and induces a change in cell morphology with fast F-actin reorganization and formation of filopodia, and promotes cancer cell invasiveness through both 2- and 3-dimensional extracellular matrices in vitro. Furthermore, P2X7 receptor sustains Cdc42 activity and the acquisition of a mesenchymal phenotype. In an immunocompetent mouse mammary cancer model, we reveal that the expression of P2X7 receptor in cancer cells, but not in the host mice, promotes tumour growth and metastasis development, which were reduced by treatment with specific P2X7 antagonists. Our results demonstrate that P2X7 receptor drives mammary tumour progression and represents a pertinent target for mammary cancer treatment.
Collapse
Affiliation(s)
- Lucie Brisson
- Inserm UMR1069-Nutrition, Growth and Cancer, University of Tours, 37032 Tours, France; (L.B.); (J.C.); (S.C.)
| | - Stéphanie Chadet
- EA4245-Transplantation, Immunology and Inflammation, University of Tours, 37032 Tours, France; (S.C.); (O.L.-C.); (B.J.); (D.T.); (P.B.); (L.-H.J.)
| | - Osbaldo Lopez-Charcas
- EA4245-Transplantation, Immunology and Inflammation, University of Tours, 37032 Tours, France; (S.C.); (O.L.-C.); (B.J.); (D.T.); (P.B.); (L.-H.J.)
| | - Bilel Jelassi
- EA4245-Transplantation, Immunology and Inflammation, University of Tours, 37032 Tours, France; (S.C.); (O.L.-C.); (B.J.); (D.T.); (P.B.); (L.-H.J.)
| | - David Ternant
- EA4245-Transplantation, Immunology and Inflammation, University of Tours, 37032 Tours, France; (S.C.); (O.L.-C.); (B.J.); (D.T.); (P.B.); (L.-H.J.)
| | - Julie Chamouton
- Inserm UMR1069-Nutrition, Growth and Cancer, University of Tours, 37032 Tours, France; (L.B.); (J.C.); (S.C.)
| | - Stéphanie Lerondel
- CNRS UPS44 TAAM, PHENOMIN, Centre d’Imagerie du Petit Animal, 45071 Orléans, France; (S.L.); (A.L.P.)
| | - Alain Le Pape
- CNRS UPS44 TAAM, PHENOMIN, Centre d’Imagerie du Petit Animal, 45071 Orléans, France; (S.L.); (A.L.P.)
| | - Isabelle Couillin
- Laboratory of Molecular and Experimental Immunology and Neurogenetics, UMR 7355, CNRS, University of Orléans, 45071 Orléans, France; (I.C.); (A.G.)
| | - Aurélie Gombault
- Laboratory of Molecular and Experimental Immunology and Neurogenetics, UMR 7355, CNRS, University of Orléans, 45071 Orléans, France; (I.C.); (A.G.)
| | | | - Stéphan Chevalier
- Inserm UMR1069-Nutrition, Growth and Cancer, University of Tours, 37032 Tours, France; (L.B.); (J.C.); (S.C.)
| | - Pierre Besson
- EA4245-Transplantation, Immunology and Inflammation, University of Tours, 37032 Tours, France; (S.C.); (O.L.-C.); (B.J.); (D.T.); (P.B.); (L.-H.J.)
| | - Lin-Hua Jiang
- EA4245-Transplantation, Immunology and Inflammation, University of Tours, 37032 Tours, France; (S.C.); (O.L.-C.); (B.J.); (D.T.); (P.B.); (L.-H.J.)
- School of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, UK
- Sino-UK Joint Laboratory of Brain Function and Injury and Department of Physiology and Pathophysiology, Xinxiang Medical University, Xinxiang 453003, China
| | - Sébastien Roger
- EA4245-Transplantation, Immunology and Inflammation, University of Tours, 37032 Tours, France; (S.C.); (O.L.-C.); (B.J.); (D.T.); (P.B.); (L.-H.J.)
- Institut Universitaire de France, 75005 Paris, France
- Correspondence: ; Tel.: +33-2-47-36-61-30
| |
Collapse
|
8
|
Giger-Pabst U, Bucur P, Roger S, Falkenstein TA, Tabchouri N, Le Pape A, Lerondel S, Demtröder C, Salamé E, Ouaissi M. Comparison of Tissue and Blood Concentrations of Oxaliplatin Administrated by Different Modalities of Intraperitoneal Chemotherapy. Ann Surg Oncol 2019; 26:4445-4451. [PMID: 31399820 DOI: 10.1245/s10434-019-07695-z] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2019] [Indexed: 01/17/2023]
Abstract
BACKGROUND Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a new technology for delivering intraperitoneal chemotherapy. It is generally assumed that with PIPAC, the ratio of peritoneal to systemic drug concentration is superior to liquid hyperthermic intraperitoneal chemotherapy (HIPEC). To date, no direct comparative data are available supporting such an assumption. MATERIALS AND METHODS Twelve 65-day-old pigs were randomly separated into three groups of four pigs each, all of which received intraperitoneal chemotherapy using the following administration methods: PIPAC with oxaliplatin 92 mg in 150 ml dextrose 5% (Group 1); PIPAC with electrostatic aerosol precipitation (ePIPAC; Group 2); or laparoscopic HIPEC (L-HIPEC) with oxaliplatin 400 mg in 4 L dextrose 5% at 42 °C (Group 3). Serial blood and peritoneal tissue concentrations of oxaliplatin were determined by spectrometry. RESULTS In all three groups, the maximum concentration of oxaliplatin in blood was detected 50-60 min after onset of the chemotherapy experiments, with no significant differences among the three groups (p = 0.7994). Blood oxaliplatin concentrations (0-30 min) were significantly higher in the L-HIPEC group compared with the ePIPAC group (p < 0.05). No difference was found for the overall systemic oxaliplatin absorption (area under the curve). Overall concentrations in the peritoneum were not different among the three groups (p = 0.4725), but were significantly higher in the visceral peritoneum in the PIPAC group (p = 0.0242). CONCLUSIONS Blood and tissue concentrations were comparable between all groups; however, depending on the intraperitoneal area examined and the time points of drug delivery, the concentrations differed significantly between the three groups.
Collapse
Affiliation(s)
- Urs Giger-Pabst
- Department of General, Visceral and Transplant Surgery, University of Münster, Münster, Germany.,Department of General Surgery, Marien Hospital Herne, Ruhr University Bochum, Herne, Germany
| | - Petru Bucur
- Department of Digestive, Oncological, Endocrine, Hepato-Biliary, Pancreatic and Liver Transplant Surgery, Trousseau Hospital, Chambray Les Tours, France
| | - Sébastien Roger
- EA4245 Transplantation Immunologie Inflammation, Université de Tours, Tours, France
| | | | - Nicolas Tabchouri
- Department of Digestive, Oncological, Endocrine, Hepato-Biliary, Pancreatic and Liver Transplant Surgery, Trousseau Hospital, Chambray Les Tours, France
| | | | | | - Cédric Demtröder
- Department of General, Visceral and Transplant Surgery, University of Münster, Münster, Germany.,Department of General Surgery, Marien Hospital Herne, Ruhr University Bochum, Herne, Germany
| | - Ephrem Salamé
- Department of Digestive, Oncological, Endocrine, Hepato-Biliary, Pancreatic and Liver Transplant Surgery, Trousseau Hospital, Chambray Les Tours, France
| | - Mehdi Ouaissi
- Department of Digestive, Oncological, Endocrine, Hepato-Biliary, Pancreatic and Liver Transplant Surgery, Trousseau Hospital, Chambray Les Tours, France. .,EA4245 Transplantation Immunologie Inflammation, Université de Tours, Tours, France.
| |
Collapse
|
9
|
Garrido MF, Martin NJP, Bertrand M, Gaudin C, Commo F, El Kalaany N, Al Nakouzi N, Fazli L, Del Nery E, Camonis J, Perez F, Lerondel S, Le Pape A, Compagno D, Gleave M, Loriot Y, Désaubry L, Vagner S, Fizazi K, Chauchereau A. Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer. Clin Cancer Res 2018; 25:710-723. [PMID: 30322877 DOI: 10.1158/1078-0432.ccr-18-0704] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2018] [Revised: 07/29/2018] [Accepted: 10/10/2018] [Indexed: 11/16/2022]
Abstract
PURPOSE Targeted therapies that use the signaling pathways involved in prostate cancer are required to overcome chemoresistance and improve treatment outcomes for men. Molecular chaperones play a key role in the regulation of protein homeostasis and are potential targets for overcoming chemoresistance.Experimental Design: We established 4 chemoresistant prostate cancer cell lines and used image-based high-content siRNA functional screening, based on gene-expression signature, to explore mechanisms of chemoresistance and identify new potential targets with potential roles in taxane resistance. The functional role of a new target was assessed by in vitro and in vivo silencing, and mass spectrometry analysis was used to identify its downstream effectors. RESULTS We identified FKBP7, a prolyl-peptidyl isomerase overexpressed in docetaxel-resistant and in cabazitaxel-resistant prostate cancer cells. This is the first study to characterize the function of human FKBP7 and explore its role in cancer. We discovered that FKBP7 was upregulated in human prostate cancers and its expression correlated with the recurrence observed in patients receiving docetaxel. FKBP7 silencing showed that FKBP7 is required to maintain the growth of chemoresistant cell lines and chemoresistant tumors in mice. Mass spectrometry analysis revealed that FKBP7 interacts with eIF4G, a component of the eIF4F translation initiation complex, to mediate the survival of chemoresistant cells. Using small-molecule inhibitors of eIF4A, the RNA helicase component of eIF4F, we were able to kill docetaxel- and cabazitaxel-resistant cells. CONCLUSIONS Targeting FKBP7 or the eIF4G-containing eIF4F translation initiation complex could be novel therapeutic strategies to eradicate taxane-resistant prostate cancer cells.
Collapse
Affiliation(s)
- Marine F Garrido
- Prostate Cancer Group, INSERM UMR981, Villejuif, France.,Univ Paris-Sud, UMR981, Villejuif, France.,Gustave Roussy, Villejuif, France
| | - Nicolas J-P Martin
- Prostate Cancer Group, INSERM UMR981, Villejuif, France.,Univ Paris-Sud, UMR981, Villejuif, France.,Gustave Roussy, Villejuif, France
| | - Matthieu Bertrand
- Prostate Cancer Group, INSERM UMR981, Villejuif, France.,Univ Paris-Sud, UMR981, Villejuif, France.,Gustave Roussy, Villejuif, France
| | - Catherine Gaudin
- Prostate Cancer Group, INSERM UMR981, Villejuif, France.,Univ Paris-Sud, UMR981, Villejuif, France.,Gustave Roussy, Villejuif, France
| | - Frédéric Commo
- Prostate Cancer Group, INSERM UMR981, Villejuif, France.,Univ Paris-Sud, UMR981, Villejuif, France.,Gustave Roussy, Villejuif, France
| | - Nassif El Kalaany
- Prostate Cancer Group, INSERM UMR981, Villejuif, France.,Univ Paris-Sud, UMR981, Villejuif, France.,Gustave Roussy, Villejuif, France
| | - Nader Al Nakouzi
- Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada
| | - Ladan Fazli
- Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada
| | - Elaine Del Nery
- Institut Curie, PSL Research University, Paris, France.,Biophenics High-Content Screening Laboratory, Cell and Tissue Imaging Facility (PICT-IBiSA), Paris, France
| | - Jacques Camonis
- Institut Curie, PSL Research University, Paris, France.,Biophenics High-Content Screening Laboratory, Cell and Tissue Imaging Facility (PICT-IBiSA), Paris, France.,INSERM, U830, Paris, France
| | - Franck Perez
- Institut Curie, PSL Research University, Paris, France.,Biophenics High-Content Screening Laboratory, Cell and Tissue Imaging Facility (PICT-IBiSA), Paris, France.,CNRS, UMR144, Paris, France
| | | | | | - Daniel Compagno
- Molecular and Functional Glyco-Oncology Lab, IQUIBICEN-CONICET, Facultad de Ciencias Exactas y Naturales-Universidad de Buenos Aires, CABA, Argentina
| | - Martin Gleave
- Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada
| | - Yohann Loriot
- Prostate Cancer Group, INSERM UMR981, Villejuif, France.,Univ Paris-Sud, UMR981, Villejuif, France.,Gustave Roussy, Villejuif, France
| | | | - Stéphan Vagner
- Institut Curie, PSL Research University, Paris, France.,CNRS, UMR3348, Orsay, France
| | - Karim Fizazi
- Prostate Cancer Group, INSERM UMR981, Villejuif, France.,Univ Paris-Sud, UMR981, Villejuif, France.,Gustave Roussy, Villejuif, France
| | - Anne Chauchereau
- Prostate Cancer Group, INSERM UMR981, Villejuif, France. .,Univ Paris-Sud, UMR981, Villejuif, France.,Gustave Roussy, Villejuif, France
| |
Collapse
|
10
|
Renoux B, Raes F, Legigan T, Péraudeau E, Eddhif B, Poinot P, Tranoy-Opalinski I, Alsarraf J, Koniev O, Kolodych S, Lerondel S, Le Pape A, Clarhaut J, Papot S. Targeting the tumour microenvironment with an enzyme-responsive drug delivery system for the efficient therapy of breast and pancreatic cancers. Chem Sci 2017; 8:3427-3433. [PMID: 28507714 PMCID: PMC5417048 DOI: 10.1039/c7sc00472a] [Citation(s) in RCA: 75] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2017] [Accepted: 03/01/2017] [Indexed: 12/21/2022] Open
Abstract
The development of novel therapeutic strategies allowing the destruction of tumour cells while sparing healthy tissues is one of the main challenges of cancer chemotherapy. Here, we report on the design and antitumour activity of a low-molecular-weight drug delivery system programmed for the selective release of the potent monomethylauristatin E in the tumour microenvironment of solid tumours. After intravenous administration, this compound binds covalently to plasmatic albumin through Michael addition, thereby enabling its passive accumulation in tumours where extracellular β-glucuronidase initiates the selective release of the drug. This targeting device produces outstanding therapeutic efficacy on orthotopic triple-negative mammary and pancreatic tumours in mice (50% and 33% of mice with the respective tumours cured), leading to impressive reduction or even disappearance of tumours without inducing side effects.
Collapse
Affiliation(s)
- Brigitte Renoux
- Institut de Chimie des Milieux et des Matériaux de Poitiers (IC2MP) , Université de Poitiers , CNRS , Groupe "Systèmes Moléculaires Programmés" , 4 rue Michel Brunet, TSA 51106 , F-86073 Poitiers , France .
| | - Florian Raes
- UPS no. 44 PHENOMIN TAAM-CIPA , CNRS , 3B rue de la Férollerie , F-45071 Orléans , France
| | - Thibaut Legigan
- Institut de Chimie des Milieux et des Matériaux de Poitiers (IC2MP) , Université de Poitiers , CNRS , Groupe "Systèmes Moléculaires Programmés" , 4 rue Michel Brunet, TSA 51106 , F-86073 Poitiers , France .
| | - Elodie Péraudeau
- Université de Poitiers , CNRS , ERL 7368, 1 rue Georges Bonnet, TSA 51106 , F-86073 Poitiers , France
- CHU de Poitiers , 2 rue de la Miléterie, CS 90577 , F-86021 Poitiers , France
| | - Balkis Eddhif
- Institut de Chimie des Milieux et des Matériaux de Poitiers (IC2MP) , Université de Poitiers , CNRS , Equipe Eau, Géochimie Organique, Santé (EGS), 4 rue Michel Brunet, TSA 51106 , F-86073 Poitiers , France
| | - Pauline Poinot
- Institut de Chimie des Milieux et des Matériaux de Poitiers (IC2MP) , Université de Poitiers , CNRS , Equipe Eau, Géochimie Organique, Santé (EGS), 4 rue Michel Brunet, TSA 51106 , F-86073 Poitiers , France
| | - Isabelle Tranoy-Opalinski
- Institut de Chimie des Milieux et des Matériaux de Poitiers (IC2MP) , Université de Poitiers , CNRS , Groupe "Systèmes Moléculaires Programmés" , 4 rue Michel Brunet, TSA 51106 , F-86073 Poitiers , France .
| | - Jérôme Alsarraf
- Institut de Chimie des Milieux et des Matériaux de Poitiers (IC2MP) , Université de Poitiers , CNRS , Groupe "Systèmes Moléculaires Programmés" , 4 rue Michel Brunet, TSA 51106 , F-86073 Poitiers , France .
| | - Oleksandr Koniev
- Syndivia SAS , 650 Bd Gonthier d'Andernach , 67400 Illkirch , France
| | - Sergii Kolodych
- Syndivia SAS , 650 Bd Gonthier d'Andernach , 67400 Illkirch , France
| | - Stéphanie Lerondel
- UPS no. 44 PHENOMIN TAAM-CIPA , CNRS , 3B rue de la Férollerie , F-45071 Orléans , France
| | - Alain Le Pape
- UPS no. 44 PHENOMIN TAAM-CIPA , CNRS , 3B rue de la Férollerie , F-45071 Orléans , France
| | - Jonathan Clarhaut
- Institut de Chimie des Milieux et des Matériaux de Poitiers (IC2MP) , Université de Poitiers , CNRS , Groupe "Systèmes Moléculaires Programmés" , 4 rue Michel Brunet, TSA 51106 , F-86073 Poitiers , France .
- CHU de Poitiers , 2 rue de la Miléterie, CS 90577 , F-86021 Poitiers , France
| | - Sébastien Papot
- Institut de Chimie des Milieux et des Matériaux de Poitiers (IC2MP) , Université de Poitiers , CNRS , Groupe "Systèmes Moléculaires Programmés" , 4 rue Michel Brunet, TSA 51106 , F-86073 Poitiers , France .
| |
Collapse
|
11
|
Arthuis CJ, Novell A, Raes F, Escoffre JM, Lerondel S, Le Pape A, Bouakaz A, Perrotin F. Real-Time Monitoring of Placental Oxygenation during Maternal Hypoxia and Hyperoxygenation Using Photoacoustic Imaging. PLoS One 2017; 12:e0169850. [PMID: 28081216 PMCID: PMC5232166 DOI: 10.1371/journal.pone.0169850] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2016] [Accepted: 12/22/2016] [Indexed: 12/15/2022] Open
Abstract
Purpose This preclinical study aimed to evaluate placental oxygenation in pregnant rats by real-time photoacoustic (PA) imaging on different days of gestation and to specify variations in placental oxygen saturation under conditions of maternal hypoxia and hyperoxygenation. Material and methods Placentas of fifteen Sprague-Dawley rats were examined on days 14, 17, and 20 of pregnancy with a PA imaging system coupled to high-resolution ultrasound imaging. Pregnant rats were successively exposed to hyperoxygenated and hypoxic conditions by changing the oxygen concentration in inhaled gas. Tissue oxygen saturation was quantitatively analyzed by real-time PA imaging in the skin and 3 regions of the placenta. All procedures were performed in accordance with applicable ethical guidelines and approved by the animal care committee. Results Maternal hypoxia was associated with significantly greater decrease in blood oxygen saturation (ΔO2 Saturation) in the skin (70.74% ±7.65) than in the mesometrial triangle (32.66% ±5.75) or other placental areas (labyrinth: 18.58% ± 6.61; basal zone: 13.13% ±5.72) on different days of pregnancy (P<0.001). ΔO2 Saturation did not differ significantly between the labyrinth, the basal zone, and the decidua. After the period of hypoxia, maternal hyperoxygenation led to a significant rise in oxygen saturation, which returned to its initial values in the different placental regions (P<0.001). Conclusions PA imaging enables the variation of blood oxygen saturation to be monitored in the placenta during maternal hypoxia or hyperoxygenation. This first preclinical study suggests that the placenta plays an important role in protecting the fetus against maternal hypoxia.
Collapse
Affiliation(s)
- Chloé J. Arthuis
- Inserm U930, François Rabelais University, Tours, France
- University Hospital Center of Tours, Department of Obstetrics, Gynecology and Fetal Medicine, Tours, France
- * E-mail:
| | - Anthony Novell
- Inserm U930, François Rabelais University, Tours, France
| | - Florian Raes
- PHENOMIN-TAAM-UPS44, Center for Small Animal Imaging (CIPA), CNRS Orléans, France
| | | | - Stéphanie Lerondel
- PHENOMIN-TAAM-UPS44, Center for Small Animal Imaging (CIPA), CNRS Orléans, France
| | - Alain Le Pape
- PHENOMIN-TAAM-UPS44, Center for Small Animal Imaging (CIPA), CNRS Orléans, France
| | - Ayache Bouakaz
- Inserm U930, François Rabelais University, Tours, France
| | - Franck Perrotin
- Inserm U930, François Rabelais University, Tours, France
- University Hospital Center of Tours, Department of Obstetrics, Gynecology and Fetal Medicine, Tours, France
| |
Collapse
|
12
|
Ilic V, Dunet V, Le Pape A, Buchs M, Kosinski M, Bischof Delaloye A, Gerber S, Prior JO. SPECT/CT study of bronchial deposition of inhaled particles. A human aerosol vaccination model against HPV. Nuklearmedizin 2016; 55:203-8. [PMID: 27440125 DOI: 10.3413/nukmed-0811-16-03] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2016] [Accepted: 06/28/2016] [Indexed: 02/01/2023]
Abstract
AIMS Vaccination by aerosol inhalation can be used to efficiently deliver antigen against HPV to mucosal tissue, which is particularly useful in developing countries (simplicity of administration, costs, no need for cold chain). For optimal immunological response, vaccine particles should preferentially be delivered to proximal bronchial airways. We aimed at quantifying the deposition of inhaled particles in central airways and peripheral lung, and to assess administration biosafety. Participants, methods: 20 healthy volunteers (13W/7M, aged 24±4y) performed a 10-min free-breathing inhalation of (99m)Tc-stannous chloride colloid aerosol (450 MBq) in a buffer solution without vaccinal particles using an ultrasonic nebulizer (mass median aerodynamic diameter 4.2 μm) and a double mask inside a biosafety cabinet dedicated to assess environmental particle release. SPECT/CT and whole-body planar scintigraphy were acquired to determine whole-body and regional C/P distribution ratio (central-to-peripheral pulmonary deposition counts). Using a phantom, SPECT sensitivity was calibrated to obtain absolute pulmonary activity deposited by inhalation. RESULTS All participants successfully performed the inhalation that was well tolerated (no change in pulmonary peak expiratory flow rate, p = 0.9). It was environmentally safe (no activity released in the biosafety filter.) 1.3±0.6% (range 0.4-2.6%) of the total nebulizer activity was deposited in the lungs with a C/P distribution ratio of 0.40±0.20 (range 0.15-1.14). CONCLUSION Quantification and regional distribution of inhaled particles in an aerosolized vaccine model is possible using radioactive particles. This will allow optimizing deposition parameters and determining the particles charge for active-particles vaccination.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - John O Prior
- Prof. John O. Prior, PhD MD, Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, Rue du Bugnon 46, 1011 Lausanne, Switzerland, Tel. +41/21/314 43-48, Fax -49,
| |
Collapse
|
13
|
Raes F, Sobilo J, Natkunarajah S, Trochet P, Fuchs D, Lerondel S, Le Pape A. Abstract 4200: Novel imaging strategy to assess the antitumor efficacy of treatments in an orthotopic mouse lung cancer model using ultrasound and photoacoustic imaging. Cancer Res 2016. [DOI: 10.1158/1538-7445.am2016-4200] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction
The aim of this study is to develop new strategies for the exploration of relevant preclinical lung tumor models dedicated to onco-pharmacology studies in mice. Here we refine a translational approach while overcoming physical ultrasound (US) imaging limitations allowing lung tumors exploration. Our data were compared to Computed Tomography (CT) and Bioluminescence (BLI) aiming to validate this promising approach.
Methods
Human lung cancer cells NCI-H460-luc2 were orthotopically xenografted in Balb/c nude mice. BLI was performed 7 days after implantation then once a week until the end of the study (Day 28) using an IVIS-Lumina II (Perkin Elmer). Tumors were imaged with the Vevo®LAZR System (FUJIFILM VisualSonics Inc.), 3D scans of US, Contrast Enhanced Ultrasound (CEUS) (Vevo MicroMarkerTM) and photoacoustic (PA) image being recorded digitally. A comparison between in vivo US and CT was achieved with additional ex vivo weight and volumetric measurements.
Results
The control of the tumor cell implantation was determined by BLI allowing the early quantification of tumor burden. 3D US measurements made possible longitudinal tumor volumes assessment. Compared to the other in vivo measurements, results clearly indicated the gross correlation of volumes processed with US and CT (R2 = 0.75). Such a correlation is also observed with ex vivo US weight and volumetric measurements (R2 = 0.72, R2 = 0.75 and R2 = 0.65 respectively). PA imaging evidenced the hemoglobin saturation with oxygen inside tumors, and targeted CEUS imaging allowed assessing the relative VEGFR2 expression in lung tumors.
Conclusions
This study proved the ability of US imaging to detect and control the in vivo orthotopic lung tumor growth. This real-time approach is fast while being completely inert regarding the in situ proliferation, as compared to dosimetry related to repeated CT examinations. Furthermore it allows overcoming the limitation of BLI at the time tumors become hypoxic since the luciferase/luciferin reaction is strictly dependent upon O2 and ATP. We described here a PA and US imaging strategy to follow the orthotopic lung tumors growth and consider biomarkers such as VEGFR2 expression or hypoxia in vivo for the first time. This procedure would be of great interest to longitudinally investigate tumor proliferation in animals when evaluating new anticancer therapies efficacy, avoiding any perturbation of the tumor progression compared to other available imaging modalities.
Citation Format: Florian Raes, Julien Sobilo, Sharuja Natkunarajah, Philippe Trochet, Dieter Fuchs, Stephanie Lerondel, Alain Le Pape. Novel imaging strategy to assess the antitumor efficacy of treatments in an orthotopic mouse lung cancer model using ultrasound and photoacoustic imaging. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4200.
Collapse
Affiliation(s)
- Florian Raes
- 1Phenomin-TAAM CIPA CNRS UPS44 French National Center for Scientific Research, Orléans, France
| | - Julien Sobilo
- 1Phenomin-TAAM CIPA CNRS UPS44 French National Center for Scientific Research, Orléans, France
| | - Sharuja Natkunarajah
- 1Phenomin-TAAM CIPA CNRS UPS44 French National Center for Scientific Research, Orléans, France
| | | | - Dieter Fuchs
- 2FUJIFILM Visualsonics Inc., Amsterdam, Netherlands
| | - Stephanie Lerondel
- 1Phenomin-TAAM CIPA CNRS UPS44 French National Center for Scientific Research, Orléans, France
| | - Alain Le Pape
- 3Phenomin-TAAM CIPA CNRS UPS44 French National Center for Scientific Research / CEPR INSERM U1100, Orléans / Tours, France
| |
Collapse
|
14
|
Desoubeaux G, Reichert JM, Sleeman M, Reckamp KL, Ryffel B, Adamczewski JP, Sweeney TD, Vanbever R, Diot P, Owen CA, Page C, Lerondel S, Le Pape A, Heuze-Vourc'h N. Therapeutic monoclonal antibodies for respiratory diseases: Current challenges and perspectives, March 31 - April 1, 2016, Tours, France. MAbs 2016; 8:999-1009. [PMID: 27266390 PMCID: PMC4968091 DOI: 10.1080/19420862.2016.1196521] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
Monoclonal antibody (mAb) therapeutics have tremendous potential to benefit patients with lung diseases, for which there remains substantial unmet medical need. To capture the current state of mAb research and development in the area of respiratory diseases, the Research Center of Respiratory Diseases (CEPR-INSERM U1100), the Laboratory of Excellence “MAbImprove,” the GDR 3260 “Antibodies and therapeutic targeting,” and the Grant Research program ARD2020 “Biotherapeutics” invited speakers from industry, academic and government organizations to present their recent research results at the Therapeutic Monoclonal Antibodies for Respiratory Diseases: Current challenges and perspectives congress held March 31 – April 1, 2016 in Tours, France.
Collapse
Affiliation(s)
- Guillaume Desoubeaux
- a Université François-Rabelais , Tours , France.,b INSERM, Center d'Etude des Pathologies Respiratoires , Tours , France.,c Centre Hospitalo-Universitaire de Tours , Tours , France
| | - Janice M Reichert
- d The Antibody Society , Framingham , MA , USA.,e Reichert Biotechnology Consulting LLC , Framingham MA , USA
| | | | - Karen L Reckamp
- g City of Hope, Comprehensive Cancer Center , Duarte , CA , USA
| | - Bernhard Ryffel
- h Université d'Orléans , Orléans , France.,i University of Cape Town, Institute of Infectious Disease and Molecular Medicine (IDM) , Cape Town , South Africa
| | | | | | - Rita Vanbever
- l Université Catholique de Louvain, Louvain Drug Research Institute , Brussels , Belgium
| | - Patrice Diot
- a Université François-Rabelais , Tours , France.,b INSERM, Center d'Etude des Pathologies Respiratoires , Tours , France.,c Centre Hospitalo-Universitaire de Tours , Tours , France
| | - Caroline A Owen
- m Harvard Medical School, Brigham and Women's Hospital , Boston , MA , USA.,n Lovelace Respiratory Research Institute , Albuquerque , NM , USA
| | - Clive Page
- o King's College, Sackler Institute of Pulmonary Pharmacology , London , UK
| | | | - Alain Le Pape
- a Université François-Rabelais , Tours , France.,b INSERM, Center d'Etude des Pathologies Respiratoires , Tours , France.,p PHENOMIN-TAAM CNRS, CIPA , Orléans , France
| | - Nathalie Heuze-Vourc'h
- a Université François-Rabelais , Tours , France.,b INSERM, Center d'Etude des Pathologies Respiratoires , Tours , France
| |
Collapse
|
15
|
Raes F, Sobilo J, Le Mée M, Rétif S, Natkunarajah S, Lerondel S, Le Pape A. High Resolution Ultrasound and Photoacoustic Imaging of Orthotopic Lung Cancer in Mice: New Perspectives for Onco-Pharmacology. PLoS One 2016; 11:e0153532. [PMID: 27070548 PMCID: PMC4829195 DOI: 10.1371/journal.pone.0153532] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2016] [Accepted: 03/30/2016] [Indexed: 11/18/2022] Open
Abstract
Objectives We have developed a relevant preclinical model associated with a specific imaging protocol dedicated to onco-pharmacology studies in mice. Materials and Methods We optimized both the animal model and an ultrasound imaging procedure to follow up longitudinally the lung tumor growth in mice. Moreover we proposed to measure by photoacoustic imaging the intratumoral hypoxia, which is a crucial parameter responsible for resistance to therapies. Finally, we compared ultrasound data to x-ray micro computed tomography and volumetric measurements to validate the relevance of this approach on the NCI-H460 human orthotopic lung tumor. Results This study demonstrates the ability of ultrasound imaging to detect and monitor the in vivo orthotopic lung tumor growth by high resolution ultrasound imaging. This approach enabled us to characterize key biological parameters such as oxygenation, perfusion status and vascularization of tumors. Conclusion Such an experimental approach has never been reported previously and it would provide a nonradiative tool for assessment of anticancer therapeutic efficacy in mice. Considering the absence of ultrasound propagation through the lung parenchyma, this strategy requires the implantation of tumors strictly located in the superficial posterior part of the lung.
Collapse
Affiliation(s)
- Florian Raes
- PHENOMIN-TAAM-UPS44, CIPA (Centre d’Imagerie du Petit Animal), CNRS Orléans, France
- * E-mail:
| | - Julien Sobilo
- PHENOMIN-TAAM-UPS44, CIPA (Centre d’Imagerie du Petit Animal), CNRS Orléans, France
| | - Marilyne Le Mée
- PHENOMIN-TAAM-UPS44, CIPA (Centre d’Imagerie du Petit Animal), CNRS Orléans, France
| | - Stéphanie Rétif
- PHENOMIN-TAAM-UPS44, CIPA (Centre d’Imagerie du Petit Animal), CNRS Orléans, France
| | - Sharuja Natkunarajah
- PHENOMIN-TAAM-UPS44, CIPA (Centre d’Imagerie du Petit Animal), CNRS Orléans, France
| | - Stéphanie Lerondel
- PHENOMIN-TAAM-UPS44, CIPA (Centre d’Imagerie du Petit Animal), CNRS Orléans, France
| | - Alain Le Pape
- PHENOMIN-TAAM-UPS44, CIPA (Centre d’Imagerie du Petit Animal), CNRS Orléans, France
- INSERM U1100, CEPR, University of Tours, France
| |
Collapse
|
16
|
Lavergne M, Jourdan ML, Blechet C, Guyetant S, Pape AL, Heuze-Vourc'h N, Courty Y, Lerondel S, Sobilo J, Iochmann S, Reverdiau P. Beneficial role of overexpression of TFPI-2 on tumour progression in human small cell lung cancer. FEBS Open Bio 2013; 3:291-301. [PMID: 23905012 PMCID: PMC3722576 DOI: 10.1016/j.fob.2013.06.004] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2013] [Revised: 06/05/2013] [Accepted: 06/23/2013] [Indexed: 12/18/2022] Open
Abstract
Tissue factor pathway inhibitor-2 (TFPI-2) is a potent inhibitor of plasmin, a protease which is involved in tumour progression by activating (MMPs). This therefore makes TFPI-2 a potential inhibitor of invasiveness and the development of metastases. In this study, low levels of TFPI-2 expression were found in 65% of patients with small cell lung cancer (SCLC), the most aggressive type of lung cancer. To study the impact of TFPI-2 in tumour progression, TFPI-2 was overexpressed in NCI-H209 SCLC cells which were orthotopically implanted in nude mice. Investigations showed that TFPI-2 inhibited lung tumour growth. Such inhibition could be explained in vitro by a decrease in tumour cell viability, blockade of G1/S phase cell cycle transition and an increase in apoptosis shown in NCI-H209 cells expressing TFPI-2. We also demonstrated that TFPI-2 upregulation in NCI-H209 cells decreased MMP expression, particularly by downregulating MMP-1 and MMP-3. Moreover, TFPI-2 inhibited phosphorylation of the MAPK signalling pathway proteins involved in the induction of MMP transcripts, among which MMP-1 was predominant in SCLC tissues and was inversely expressed with TFPI-2 in 35% of cases. These results suggest that downregulation of TFPI-2 expression could favour the development of SCLC. The Tissue Factor Pathway Inhibitor-2 inhibits small cell lung cancer growth Monitoring of small cell lung cancer growth in a mouse orthotopic model by imaging Increasing information on the role of TFPI-2 in human lung tumour cells Increasing information on TFPI-2 and protease expression in human tissue samples
Collapse
Affiliation(s)
- Marion Lavergne
- EA 6305, Université François Rabelais de Tours, Tours F-37032, France ; Centre d'Etude des Pathologies Respiratoires, UMR 1100/EA6305, Tours F-37032, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
|
18
|
Brullé L, Vandamme M, Riès D, Martel E, Robert E, Lerondel S, Trichet V, Richard S, Pouvesle JM, Le Pape A. Effects of a non thermal plasma treatment alone or in combination with gemcitabine in a MIA PaCa2-luc orthotopic pancreatic carcinoma model. PLoS One 2012; 7:e52653. [PMID: 23300736 PMCID: PMC3530450 DOI: 10.1371/journal.pone.0052653] [Citation(s) in RCA: 132] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2012] [Accepted: 11/19/2012] [Indexed: 12/01/2022] Open
Abstract
Pancreatic tumors are the gastrointestinal cancer with the worst prognosis in humans and with a survival rate of 5% at 5 years. Nowadays, no chemotherapy has demonstrated efficacy in terms of survival for this cancer. Previous study focused on the development of a new therapy by non thermal plasma showed significant effects on tumor growth for colorectal carcinoma and glioblastoma. To allow targeted treatment, a fibered plasma (Plasma Gun) was developed and its evaluation was performed on an orthotopic mouse model of human pancreatic carcinoma using a MIA PaCa2-luc bioluminescent cell line. The aim of this study was to characterize this pancreatic carcinoma model and to determine the effects of Plasma Gun alone or in combination with gemcitabine. During a 36 days period, quantitative BLI could be used to follow the tumor progression and we demonstrated that plasma gun induced an inhibition of MIA PaCa2-luc cells proliferation in vitro and in vivo and that this effect could be improved by association with gemcitabine possibly thanks to its radiosensitizing properties.
Collapse
Affiliation(s)
- Laura Brullé
- Centre d'Imagerie du Petit Animal-CIPA TAAM, UPS44 CNRS, Orléans, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Vandamme M, Brullé L, Ries D, Robert E, Sarron V, Dozias S, Lerondel S, Pouvesle JM, Pape AL. Abstract 2839: Antitumor activity on colorectal and pancreatic tumors of a new strategy based on ROS generation by non-thermal plasma. Cancer Res 2012. [DOI: 10.1158/1538-7445.am2012-2839] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background. Local treatments of tumors are mainly based on surgical resection and/or treatment such as photodynamic therapy (PDT) or ionizing radiation (IR). Action mechanisms of IR and PDT are based on the generation of ROS in the vicinity of the cells. In this context, cold or Non Thermal Plasma (NTP), a new technology which can generate in situ ROS, is currently under investigations. NTP is a cold (<40°C) ionized gas (air or noble gas) thank to an electric discharge. It contains free charges (electrons, ions), free radicals and excited molecules. NTP can be generated at the end of a catheter (plasma jet) allowing a local treatment that is compatible with usual endoscopes for dysplasia or non resecable tumors. Previous studies have shown an in vitro antitumor activity of NTP on various cells lines and in vivo on subcutaneous xenografts. The aim of this work was to assess the antitumor potential of fibred NTP when applied directly on in situ orthotopic human pancreatic or colorectal carcinoma xenografts. Methods. For in vitro experiments, HCT116-Luc and Mia Paca-Luc cells were seeded in 24-well plate and then treated with a plasma jet device called plasma gun. The effects on cells were assessed by bioluminescence imaging (BLI). For in vivo experiments, HCT116-Luc cells were xenografted in the caecum wall of nude mice and tumors were treated by a single NTP exposure 7 days post-induction. Concerning pancreatic tumors, MIA PaCa2-Luc cells were injected in the pancreas head and NTP treatments were started 4 days after implantation. Two others exposures were performed on D14 and D24. For both models, tumor growth was monitored by BLI once a week. Results and Discussion. NTP treatment showed a significant antitumor effect on HCT116 and Mia Paca cells in vitro and in vivo. In vitro plasma induced a decrease of BLI resulting from a massive cell death. Localized treatments of tumor using plasma gun induced significant tumor stabilization. On colorectal tumors, a BLI difference of 90% between treated and CTRL tumors were observed at D22. This effect was confirmed by tumor weight measurement. Moreover, a significant metastasis decrease was observed. Similar results were observed on pancreatic tumors with also a stabilization of tumor growth and a BLI decrease following each treatment leading finally at D36 to a significant difference of tumor volume (84%). Comparison of NTP with the references drug of these pathologies is ongoing. The results obtained on two different tumor types show the potential antitumor activity of NTP on implanted small tumors. These effects were linked to a high rate generation of ROS in the vicinity of tumors, inducing lethal DNA damages, a multiphase cell cycle arrest and finally apoptosis. Such results demonstrate the interest of NTP for treatment of dysplasia and non-resecable tumors that could be associated to real time per operative near infrared fluorescence imaging via fibro/coelioscopy.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2839. doi:1538-7445.AM2012-2839
Collapse
Affiliation(s)
- Marc Vandamme
- 1Germitec SAS, CIPA TAAM UPS44 & GREMI UMR6606, Orleans Cedex 2, France
| | | | | | - Eric Robert
- 3GREMI UMR-6606 CNRS, Orleans Cedex 2, France
| | | | | | | | | | - Alain Le Pape
- 4Inserm U618, Tours & CIPA TAAM UPS44 CNRS, Orleans Cedex 2, France
| |
Collapse
|
20
|
|
21
|
Iochmann S, Lerondel S, Bléchet C, Lavergne M, Pesnel S, Sobilo J, Heuzé-Vourc'h N, Le Pape A, Reverdiau P. Monitoring of tumour progression using bioluminescence imaging and computed tomography scanning in a nude mouse orthotopic model of human small cell lung cancer. Lung Cancer 2012; 77:70-6. [PMID: 22321610 DOI: 10.1016/j.lungcan.2012.01.009] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2011] [Revised: 12/23/2011] [Accepted: 01/15/2012] [Indexed: 11/18/2022]
Abstract
Human small cell lung carcinoma (SCLC) is the most aggressive type of lung cancer but no clinically relevant animal model has been developed to date. Such a model would be valuable to study the molecular aspects of tumour progression and to test the effectiveness of new treatment agents. We generated a reproducible and reliable nude mouse orthotopic model of human SCLC with NCI-H209 tumour cells genetically modified to express firefly luciferase. Cells were analysed for long-term stability of bioluminescence and a clone was passaged twice subcutaneously to enhance tumorigenicity. Cells resuspended in Matrigel and/or EDTA RPMI medium containing a (99m)Tc-labelled tin colloid used as tracer were implanted intrabronchially with a catheter inserted into the trachea and positioned in the main bronchus using X-ray-guided imaging. Deposition of cells into the lung was then assessed by scintigraphy. The growth of the primary tumour was sensitively and non-invasively followed by bioluminescence imaging that allowed real-time monitoring of tumour progression in the same animals over a 2-12-week period. Additional 3D bioluminescence imaging and computed tomography scanning were used to document tumour location and measurements that were confirmed by histological analyses. In conclusion, this original nude mouse orthotopic model resembles various stages of human small cell lung cancer, and therefore could be used to evaluate new treatment strategies.
Collapse
Affiliation(s)
- Sophie Iochmann
- Inserm U618, Université François Rabelais, IFR 135, F-37032 Tours, France
| | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Pesnel S, Pillon A, Créancier L, Lerondel S, Le Pape A, Recher C, Demur C, Guilbaud N, Kruczynski A. Optical imaging of disseminated leukemia models in mice with near-infrared probe conjugated to a monoclonal antibody. PLoS One 2012; 7:e30690. [PMID: 22303450 PMCID: PMC3267751 DOI: 10.1371/journal.pone.0030690] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2011] [Accepted: 12/22/2011] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND The assessment of anticancer agents to treat leukemia needs to have animal models closer to the human pathology such as implantation in immunodeficient mice of leukemic cells from patient samples. A sensitive and early detection of tumor cells in these orthotopic models is a prerequisite for monitoring engraftment of leukemic cells and their dissemination in mice. Therefore, we developed a fluorescent antibody based strategy to detect leukemic foci in mice bearing patient-derived leukemic cells using fluorescence reflectance imaging (FRI) to determine when to start treatments with novel antitumor agents. METHODS Two mAbs against the CD44 human myeloid marker or the CD45 human leukocyte marker were labeled with Alexa Fluor 750 and administered to leukemia-bearing mice after having verified the immunoreactivity in vitro. Bioluminescent leukemic cells (HL60-Luc) were used to compare the colocalization of the fluorescent mAb with these cells. The impact of the labeled antibodies on disease progression was further determined. Finally, the fluorescent hCD45 mAb was tested in mice engrafted with human leukemic cells. RESULTS The probe labeling did not modify the immunoreactivity of the mAbs. There was a satisfactory correlation between bioluminescence imaging (BLI) and FRI and low doses of mAb were sufficient to detect leukemic foci. However, anti-hCD44 mAb had a strong impact on the tumor proliferation contrary to anti-hCD45 mAb. The use of anti-hCD45 mAb allowed the detection of leukemic patient cells engrafted onto NOD/SCID mice. CONCLUSIONS A mAb labeled with a near infrared fluorochrome is useful to detect leukemic foci in disseminated models provided that its potential impact on tumor proliferation has been thoroughly documented.
Collapse
MESH Headings
- Animals
- Antibodies, Monoclonal/administration & dosage
- Antibodies, Monoclonal/immunology
- Cell Line, Tumor
- Cell Transformation, Neoplastic/pathology
- Disease Models, Animal
- Flow Cytometry
- Fluorescent Dyes/metabolism
- Humans
- Imaging, Three-Dimensional/methods
- Injections, Intravenous
- Leukemia/diagnosis
- Leukemia/pathology
- Leukemia, Myeloid, Acute/pathology
- Leukocyte Common Antigens/metabolism
- Longevity
- Luminescent Measurements
- Mice
- Mice, SCID
- Reproducibility of Results
- Spectroscopy, Near-Infrared/methods
Collapse
Affiliation(s)
- Sabrina Pesnel
- Centre de Recherche en Oncologie Expérimentale, Institut de Recherche Pierre Fabre, Toulouse, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Robert E, Vandamme M, Sobilo J, Sarron V, Ries D, Dozias S, Brulle L, Lerondel S, Le Pape A, Pouvesle JM. First Achievements and Opportunities for Cancer Treatment Using Non-thermal Plasma. Plasma for Bio-Decontamination, Medicine and Food Security 2012. [DOI: 10.1007/978-94-007-2852-3_29] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
|
24
|
Pesnel S, Akkoul S, Ledée R, Leconge R, Pillon A, Kruczynski A, Harba R, Lerondel S, Le Pape A. Use of an image restoration process to improve spatial resolution in bioluminescence imaging. Mol Imaging 2011; 10:446-452. [PMID: 22201535] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023] Open
Abstract
To improve spatial resolution in in vivo bioluminescence imaging, a photon scattering correction, image restoration method was tested. The chosen algorithm was tested on in vivo bioluminescent images acquired on three representative tumor models: subcutaneous, pulmonary, and disseminated peritoneal. Tumor size was chosen as a quantitative criterion, such that the tumor reference measurements (determined photographically or by computed tomography) were compared to those derived from bioluminescent images, before and after restoration. This technique allowed a significant reduction to be achieved in the relative error between reference measurements and dimensions derived from bioluminescent images. In addition, improved delineation of the tumor foci was achieved. The restoration method allows spatial resolution in bioluminescence imaging to be improved, with interesting perspectives in terms of staging and quantitation in experimental oncology.
Collapse
|
25
|
Pesnel S, Akkoul S, Ledée R, Leconge R, Pillon A, Kruczynski A, Harba R, Lerondel S, Le Pape A. Use of an Image Restoration Process to Improve Spatial Resolution in Bioluminescence Imaging. Mol Imaging 2011. [DOI: 10.2310/7290.2011.00012] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
To improve spatial resolution in in vivo bioluminescence imaging, a photon scattering correction, image restoration method was tested. The chosen algorithm was tested on in vivo bioluminescent images acquired on three representative tumor models: subcutaneous, pulmonary, and disseminated peritoneal. Tumor size was chosen as a quantitative criterion, such that the tumor reference measurements (determined photographically or by computed tomography) were compared to those derived from bioluminescent images, before and after restoration. This technique allowed a significant reduction to be achieved in the relative error between reference measurements and dimensions derived from bioluminescent images. In addition, improved delineation of the tumor foci was achieved. The restoration method allows spatial resolution in bioluminescence imaging to be improved, with interesting perspectives in terms of staging and quantitation in experimental oncology.
Collapse
Affiliation(s)
- Sabrina Pesnel
- From UPS n°44 TAAM – CIPA, CNRS, Orléans, France; Institut PRISME, Université d'Orléans, Orléans, France; Centre de Recherche en Oncologie Expérimentale, Institut de Recherche Pierre Fabre, Toulouse, France; and INSERM U618, UniversitAeA de Tours, Tours, France
| | - Smaïl Akkoul
- From UPS n°44 TAAM – CIPA, CNRS, Orléans, France; Institut PRISME, Université d'Orléans, Orléans, France; Centre de Recherche en Oncologie Expérimentale, Institut de Recherche Pierre Fabre, Toulouse, France; and INSERM U618, UniversitAeA de Tours, Tours, France
| | - Roger Ledée
- From UPS n°44 TAAM – CIPA, CNRS, Orléans, France; Institut PRISME, Université d'Orléans, Orléans, France; Centre de Recherche en Oncologie Expérimentale, Institut de Recherche Pierre Fabre, Toulouse, France; and INSERM U618, UniversitAeA de Tours, Tours, France
| | - Rémy Leconge
- From UPS n°44 TAAM – CIPA, CNRS, Orléans, France; Institut PRISME, Université d'Orléans, Orléans, France; Centre de Recherche en Oncologie Expérimentale, Institut de Recherche Pierre Fabre, Toulouse, France; and INSERM U618, UniversitAeA de Tours, Tours, France
| | - Arnaud Pillon
- From UPS n°44 TAAM – CIPA, CNRS, Orléans, France; Institut PRISME, Université d'Orléans, Orléans, France; Centre de Recherche en Oncologie Expérimentale, Institut de Recherche Pierre Fabre, Toulouse, France; and INSERM U618, UniversitAeA de Tours, Tours, France
| | - Anna Kruczynski
- From UPS n°44 TAAM – CIPA, CNRS, Orléans, France; Institut PRISME, Université d'Orléans, Orléans, France; Centre de Recherche en Oncologie Expérimentale, Institut de Recherche Pierre Fabre, Toulouse, France; and INSERM U618, UniversitAeA de Tours, Tours, France
| | - Rachid Harba
- From UPS n°44 TAAM – CIPA, CNRS, Orléans, France; Institut PRISME, Université d'Orléans, Orléans, France; Centre de Recherche en Oncologie Expérimentale, Institut de Recherche Pierre Fabre, Toulouse, France; and INSERM U618, UniversitAeA de Tours, Tours, France
| | - Stéphanie Lerondel
- From UPS n°44 TAAM – CIPA, CNRS, Orléans, France; Institut PRISME, Université d'Orléans, Orléans, France; Centre de Recherche en Oncologie Expérimentale, Institut de Recherche Pierre Fabre, Toulouse, France; and INSERM U618, UniversitAeA de Tours, Tours, France
| | - Alain Le Pape
- From UPS n°44 TAAM – CIPA, CNRS, Orléans, France; Institut PRISME, Université d'Orléans, Orléans, France; Centre de Recherche en Oncologie Expérimentale, Institut de Recherche Pierre Fabre, Toulouse, France; and INSERM U618, UniversitAeA de Tours, Tours, France
| |
Collapse
|
26
|
Vandamme M, Robert E, Lerondel S, Sarron V, Ries D, Dozias S, Sobilo J, Gosset D, Kieda C, Legrain B, Pouvesle JM, Pape AL. ROS implication in a new antitumor strategy based on non-thermal plasma. Int J Cancer 2011; 130:2185-94. [PMID: 21702038 DOI: 10.1002/ijc.26252] [Citation(s) in RCA: 274] [Impact Index Per Article: 21.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2011] [Accepted: 05/30/2011] [Indexed: 12/14/2022]
Abstract
Non-thermal plasma (NTP) is generated by ionizing neutral gas molecules/atoms leading to a highly reactive gas at ambient temperature containing excited molecules, reactive species and generating transient electric fields. Given its potential to interact with tissue or cells without a significant temperature increase, NTP appears as a promising approach for the treatment of various diseases including cancer. The aim of our study was to evaluate the interest of NTP both in vitro and in vivo. To this end, we evaluated the antitumor activity of NTP in vitro on two human cancer cell lines (glioblastoma U87MG and colorectal carcinoma HCT-116). Our data showed that NTP generated a large amount of reactive oxygen species (ROS), leading to the formation of DNA damages. This resulted in a multiphase cell cycle arrest and a subsequent apoptosis induction. In addition, in vivo experiments on U87MG bearing mice showed that NTP induced a reduction of bioluminescence and tumor volume as compared to nontreated mice. An induction of apoptosis was also observed together with an accumulation of cells in S phase of the cell cycle suggesting an arrest of tumor proliferation. In conclusion, we demonstrated here that the potential of NTP to generate ROS renders this strategy particularly promising in the context of tumor treatment.
Collapse
|
27
|
Pesnel S, Guminski Y, Pillon A, Lerondel S, Imbert T, Guilbaud N, Kruczynski A, Bailly C, Le Pape A. 99mTc-HYNIC-spermine for imaging polyamine transport system-positive tumours: preclinical evaluation. Eur J Nucl Med Mol Imaging 2011; 38:1832-41. [PMID: 21660624 DOI: 10.1007/s00259-011-1857-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2011] [Accepted: 05/26/2011] [Indexed: 11/28/2022]
Abstract
PURPOSE F14512 exploiting the polyamine transport system (PTS) for tumour cell delivery has been described as a potent antitumour agent. The optimal use of this compound will require a probe to identify tumour cells expressing a highly active PTS that might be more sensitive to the treatment. The aim of this study was to design and characterize a scintigraphic probe to evaluate its uptake in cancer cells expressing the PTS. METHODS Three polyamines coupled to a hydrazinonicotinamide (HYNIC) moiety were synthesized and labelled with 99mTc. Their radiochemical purity was determined by HPLC. The plasma stability of the 99mTc-HYNIC-spermine probe and its capacity to accumulate into PTS-active cells were also evaluated. In vitro internalization was tested using murine melanoma B16/F10 cells and human lung carcinoma A549 cells. Biodistribution was determined in healthy mice and tumour uptake was studied in B16/F10 tumour-bearing mice. A HL-60-Luc human leukaemia model was used to confront single photon emission computed tomography (SPECT) images obtained with the 99mTc-labelled probe with those obtained by bioluminescence. RESULTS The 99mTc-HYNIC-spermine probe was selected for its capacity to accumulate into PTS-active cells and its stability in plasma. In vitro studies demonstrated that the probe was internalized in the cells via the PTS. In vivo measurements indicated a tumour to muscle scintigraphic ratio of 7.9±2.8. The combined bioluminescence and scintigraphic analyses with the leukaemia model demonstrated that the spermine conjugate accumulates into the tumour cells. CONCLUSION The 99mTc-HYNIC-spermine scintigraphic probe is potentially useful to characterize the PTS activity of tumours. Additional work is needed to determine if this novel conjugate may be useful to analyse the PTS status of patients with solid tumours.
Collapse
Affiliation(s)
- Sabrina Pesnel
- Centre de Recherche en Oncologie Expérimentale, Institut de Recherche Pierre Fabre, Toulouse, France,
| | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Vandamme M, Robert E, Dozias S, Sobilo J, Lerondel S, Le Pape A, Pouvesle JM. Response of Human Glioma U87 Xenografted on Mice to Non Thermal Plasma Treatment. Plasma Med 2011. [DOI: 10.1615/plasmamed.v1.i1.30] [Citation(s) in RCA: 101] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
29
|
Vandamme M, Robert E, Sobilo J, Sarron V, Dozias S, Lerondel S, Pouvesle JM, Pape AL. Abstract 505: Plasma treatment induces apoptosis in U87 cells in vitro and in vivo. Cancer Res 2010. [DOI: 10.1158/1538-7445.am10-505] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Over the past few years, nonthermal atmospheric pressure plasma has emerged as a novel promising tool in medicine. Plasma is a partially ionized gas sustained by a supply of energy in various forms (electric, thermal, radiative . . .). Plasma contains free charges (electrons, ions), free radicals, excited molecules, energetic photons (UV) and generates transient electric fields. Studies have demonstrated an antitumor effect of plasma treatment on melanoma cells lines and our group has recently demonstrated an antitumor effect of plasma treatment on U87 glioma bearing mice.
The aim of this work was to better understand the mechanisms involved in the antitumor effect of plasma treatment observed on U87 glioma cells in vitro and in vivo.
Methods
The experiments were performed using a floating electrode DBD plasma reactor. For in vitro experiments, 24-well plate were seeded with U87 cells previously transfected by the luciferase gene (U87-Luc). Cells were treated by a single fraction of plasma. Effects of treatment on proliferation and viability were assessed by bioluminescence imaging (BLI), MTT assay and by trypan blue assay.
For in vivo experiments, malignant glioma U87 model was heterotopically implanted in nude mice. When tumors reached 150 mm3, mice were randomly assigned into two groups: CTRL and Plasma. Plasma was delivered as a daily fraction of 6 min at 200Hz for five consecutive days and tumors were imaged by bioluminescence before treatment and 24h after the first and the last fraction. Treatment effects on tumor cells proliferation and apoptosis were assessed 24h after the last fraction by determination of cell cycle distribution and detection of annexin V positive cells, respectively.
Results and Discussion
Plasma treatment showed a significant antitumoral effect on U87 glioma in vitro and in vivo. In vitro plasma induced a decrease of BLI resulting from a massive cell death. Moreover, in vivo experiments, plasma treated tumors presented an important BLI decrease of ∼70% associated with a ∼60% reduction of tumor volume as compared to CTRL. Such results are particularly encouraging in this high chemo and radioresistant model. Cell cycle distribution and annexin V analysis showed a marked apoptosis induction in the treated group. To our knowledge, only in vitro experiments have reported an apoptosis induction of plasma treatment on melanoma cell lines. DNA double strand break and ROS formation have been reported in vitro during plasma treatment and these mechanisms may participate in the induction of apoptosis observed in vivo.
Our data highlight a major antitumor effect of plasma treatment both in vitro and in vivo and this effect may be linked to an apoptosis induction. Further studies are ongoing to elucidate mechanism of action of plasma in apoptosis induction and to understand the implication of the different plasma components in the cytotoxic effect. These results will allow us to develop more efficient plasma types.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 505.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Alain Le Pape
- 4CIPA - UPS44 CNRS / Inserm U618, Orleans / Tours, France
| |
Collapse
|
30
|
Roux S, Faure AC, Mandon C, Dufort S, Rivière C, Bridot JL, Mutelet B, Marquette CA, Josserand V, Le Duc G, Le Pape A, Billotey C, Janier M, Coll JL, Perriat P, Tillement O. Multifunctional gadolinium oxide nanoparticles: towards image-guided therapy. ACTA ACUST UNITED AC 2010. [DOI: 10.2217/iim.10.5] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
31
|
Chemin C, Péan JM, Pape AL, Delbos JM, German-Fattal M, Wüthrich P, Couvreur P. Biodistribution and anticancer activity of a newvincaalkaloid encapsulated into long-circulating liposomes. J Liposome Res 2010; 20:62-72. [DOI: 10.3109/08982100903103888] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
32
|
Kruczynski A, Recher C, Pourtau S, Cartron V, Marty F, Vandenberghe I, Chansard N, Gallay N, Pillon A, Pesnel S, Le Pape A, Créancier L, Menon Y, Gomes B, Blanchet JC, Ricome C, Guminski Y, Imbert T, Payrastre B, Bailly C, Demur C, Guilbaud N. Abstract B186: Preclinical antileukemic activity of F14512, a novel targeted cytotoxic agent. Mol Cancer Ther 2009. [DOI: 10.1158/1535-7163.targ-09-b186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Despite advances in the therapy of acute myeloid leukemia (AML), the majority of patients die from their disease. Therefore, the lack of effective therapy mandates the development of novel compounds to improve the outcome of patients with relapsed and refractory leukemias. F14512 is a potent spermine-epipodophyllotoxin conjugate exploiting the polyamine transport system for tumor cell delivery. In this study, we report the in vivo antitumor activity of F14512 against experimental models of AML cell lines and of patient AML samples. F14512 markedly reduced the growth of HL-60 and U937 cell lines in an in vivo xenotransplantation model, resulting in a highly significant increase of survival of leukemia-bearing mice. Etoposide evaluated concurrently demonstrated only moderate in vivo activity against these models. F14512 induced in vivo apoptosis of HL-60 cells, as shown by caspase-3 activation and PARP cleavage. In an effort to mimic the human disease, we injected approximately 106 AML cells collected from a patient into NOD/SCID mice and allowed them to establish as xenografts for 8 weeks. Subsequent treatment with F14512 was carried out for 2 or 3 weeks followed by the analysis at the end of treatment and 1 week after the end of treatment. Two human AML samples were analyzed. Multiple i.v. administrations of F14512 at 0.32 mg/kg, induced an extensive reduction of the number of leukemic cells in mouse bone marrow and blood (97–99%), assessed by flow cytometry analysis, quantitative RT-PCR and histology. To identify leukemic cells expressing an active polyamine transport system, we developed a functional method based on the measurement of the cellular uptake of a nitrobenzoxadiazole fluorescent probe (F96982) combining the same spermine moiety as F14512. The level of fluorescence emitted by the probe F96982 was high in HL-60 cells as well in the 2 patient AML samples that proved to be sensitive to F14512 in vivo. Collectively, these results demonstrated that F14512 exhibits a marked in vivo antileukemic activity, supporting its clinical development. Phase I clinical trials in onco-hematology are now initiated with this novel promising drug candidate.
Citation Information: Mol Cancer Ther 2009;8(12 Suppl):B186.
Collapse
Affiliation(s)
| | - Christian Recher
- 2 Service d'Hématologie, Hôpital Purpan, CHU de Toulouse, Toulouse, France
| | | | | | - Fabien Marty
- 1 Institut de Recherche Pierre Fabre, Toulouse, France
| | | | | | - Nathalie Gallay
- 3 INSERM U563, Centre de Physiopathologie, CHU Purpan, Toulouse, France
| | - Arnaud Pillon
- 1 Institut de Recherche Pierre Fabre, Toulouse, France
| | | | | | | | - Yoann Menon
- 1 Institut de Recherche Pierre Fabre, Toulouse, France
| | - Bruno Gomes
- 1 Institut de Recherche Pierre Fabre, Toulouse, France
| | | | | | - Yves Guminski
- 1 Institut de Recherche Pierre Fabre, Toulouse, France
| | | | - Bernard Payrastre
- 3 INSERM U563, Centre de Physiopathologie, CHU Purpan, Toulouse, France
| | | | - Cécile Demur
- 2 Service d'Hématologie, Hôpital Purpan, CHU de Toulouse, Toulouse, France
| | | |
Collapse
|
33
|
Chemin C, Péan JM, Pape AL, Delbos JM, German-Fattal M, Wüthrich P, Couvreur P. Biodistribution and anticancer activity of a newvincaalkaloid encapsulated into long-circulating liposomes. J Liposome Res 2009. [DOI: 10.1080/08982100903103888] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
34
|
Bridot JL, Dayde D, Rivière C, Mandon C, Billotey C, Lerondel S, Sabattier R, Cartron G, Le Pape A, Blondiaux G, Janier M, Perriat P, Roux S, Tillement O. Hybrid gadolinium oxide nanoparticles combining imaging and therapy. ACTA ACUST UNITED AC 2009. [DOI: 10.1039/b815836c] [Citation(s) in RCA: 61] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
35
|
Gagnadoux F, Hureaux J, Vecellio L, Urban T, Le Pape A, Valo I, Montharu J, Leblond V, Boisdron-Celle M, Lerondel S, Majoral C, Diot P, Racineux JL, Lemarie E. Aerosolized chemotherapy. J Aerosol Med Pulm Drug Deliv 2008; 21:61-70. [PMID: 18518832 DOI: 10.1089/jamp.2007.0656] [Citation(s) in RCA: 100] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
Regional chemotherapy has been proposed as a treatment modality in a number of cancer settings. In primary or metastatic lung cancer, administration of chemotherapy via inhalation could increase exposure of lung tumor to the drug, while minimizing systemic side effects. Several proof of concept studies in animal models of metastatic or primary lung cancer have demonstrated the safety, pharmacokinetic advantage, and antitumor effect of aerosol administration of several chemotherapeutic agents including doxorubicin, gemcitabine and liposome-encapsulated formulations of paclitaxel and 9-nitrocamptothecin (9-NC). Recent phase I studies have demonstrated the feasibility of aerosol delivery of doxorubicin and liposomal formulations of 9-NC and cisplatin in patients with primary and metastatic lung cancer with a limited pharmacokinetic profile consistent with the observed low systemic toxicity. Further studies integrating safety, pharmacokinetic, and efficacy considerations are required to determine whether there is a place for local administration of chemotherapy via inhalation in lung cancer.
Collapse
|
36
|
Dubus JC, Montharu J, Vecellio L, De Monte M, De Muret A, Goucher A, Cantagrel S, Le Pape A, Mezzi K, Majoral C, Le Guellec S, Diot P. Lung deposition of HFA beclomethasone dipropionate in an animal model of bronchopulmonary dysplasia. Pediatr Res 2007; 61:21-5. [PMID: 17211135 DOI: 10.1203/01.pdr.0000250055.26148.42] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
The best delivery of a drug in ventilated neonates is obtained when using a small particle diameter solution administered via a spacer. Lung deposition of hydrofluoroalkane beclomethasone dipropionate (QVAR, 1.3 microm particles), delivered via an Aerochamber-MV15, was measured in piglets under conditions mimicking ventilated severely ill neonates (uncuffed 2.5 mm endotracheal tube; peak pressure 16 cm H2O; respiratory rate 40/min). After determining the mass and particle size distribution of the 99mTc-labeled and unlabeled drug, three lung deposition studies were performed: after 1 h of ventilation (controls, n = 18), after 48 h aggressive ventilation inducing an acute lung injury (nine piglets out of the controls), and after increasing the pressure to 24 cm H2O during drug delivery (five piglets out of the nine with acute lung injury). All piglets were then killed for lung histology. Results (median, range), expressed as a percentage of the delivered dose, were compared using an inferential or the Friedman test. While lung deposition was low, it was greater (p = 0.003) in controls (2.66%, 0.50-7.70) than in piglets with histologically confirmed acute lung injury (0.26%, 0.06-1.28) or under a high-pressure ventilation (1.01%, 0.30-2.15). Lung deposition of QVAR in an animal model of ventilated neonates is low, variable, and dramatically affected by lung injury.
Collapse
|
37
|
Gagnadoux F, Pape AL, Lemarié E, Lerondel S, Valo I, Leblond V, Racineux JL, Urban T. Aerosol delivery of chemotherapy in an orthotopic model of lung cancer. Eur Respir J 2006; 26:657-61. [PMID: 16204597 DOI: 10.1183/09031936.05.00017305] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The aim of this study was to evaluate the effect on tumour growth of gemcitabine delivered by aerosol in an orthotopic model of lung carcinoma. Large cell carcinoma (NCI-H460) cells were implanted intrabronchially in 24 male BALB/c nude mice on day (d) 0. Aerosols were delivered once a week from d1 to d29 using an endotracheal sprayer. Altogether, 16 animals received gemcitabine at 8 (n=8) and 12 mg.kg-1 (n=8), and eight received a vehicle aerosol. Animals were sacrificed on d36 for histological examination. All animals in the vehicle group developed a large infiltrating carcinoma. Comparatively, four of 13 (31%) animals treated with gemcitabine had no visible tumour and nine of 13 (69%) had a smaller carcinoma with a mean+/-sem largest tumour diameter of 2.05+/-0.7 versus 5+/-0.3 mm in the vehicle group. Gemcitabine was well tolerated at 8 mg.kg-1. At 12 mg.kg-1, three cases of fatal pulmonary oedema were observed, prompting a dose reduction to 8 mg.kg-1 in the remaining animals. A dose effect was observed, with more marked tumour growth inhibition in the animals treated at 12 mg.kg-1 on d1 and d8. In conclusion, in this study, an animal model of aerosolised chemotherapy in lung cancer was developed and demonstrated inhibition of orthotopic tumour growth by aerosol delivery of gemcitabine.
Collapse
Affiliation(s)
- F Gagnadoux
- Groupe de pneumologie, INSERM, U618, Faculté de Médecine, Tours, France.
| | | | | | | | | | | | | | | |
Collapse
|
38
|
Gagnadoux F, Leblond V, Vecellio L, Hureaux J, Le Pape A, Boisdron-Celle M, Montharu J, Majoral C, Fournier J, Urban T, Diot P, Racineux JL, Lemarié E. Gemcitabine aerosol: in vitro antitumor activity and deposition imaging for preclinical safety assessment in baboons. Cancer Chemother Pharmacol 2005; 58:237-44. [PMID: 16328414 DOI: 10.1007/s00280-005-0146-9] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2005] [Accepted: 10/12/2005] [Indexed: 10/25/2022]
Abstract
AIM To characterize gemcitabine aerosol, its in vitro activity against lung cancer cells, its deposition, and tolerance in a non-human primate model. METHODS In vitro cytotoxicity of nebulized gemcitabine against NCI-H460 and A549 lung cancer cells was tested using a growth inhibition assay and compared with non-nebulized gemcitabine. The (99m)Tc-DTPA-radiolabeled gemcitabine aerosol was characterized by cascade impaction and the gemcitabine mass/(99m)Tc activity relationship was established for further quantitative nuclear imaging. Nine weekly inhalations at a target dose of 1 mg/kg body weight of gemcitabine were performed in three baboons using dynamic scintigraphic acquisitions for continuous monitoring of gemcitabine delivery during inhalation. Gemcitabine plasma concentrations were measured during the first inhalation. RESULTS Growth inhibition assays for both NCI-H460 and A549 cells did not differ between nebulized and non-nebulized gemcitabine. Aerosol characterization showed a particle mass median aerodynamic diameter of 3.7+/-0.8 microm and a linear relationship between gemcitabine mass (y) and (99m)Tc activity (x) (y=0.82x - 10(-5), R (2)=0.88). No toxicity was observed after nine weekly inhalations of a mean dose of gemcitabine of 11.1 mg (88% of the target dose) as assessed from scintigraphic data. A dose-dependent peak plasma concentration of gemcitabine (20-74 ng/ml) was observed by the tenth minute of inhalation. CONCLUSIONS We have characterized a gemcitabine aerosol suitable for intrathoracic airway deposition and demonstrated that jet nebulization does not alter the cytotoxic properties of the drug. In a primate model, we have developed a scintigraphic procedure for the monitoring of aerosol deposition, and we have demonstrated the safety of nine weekly aerosol administrations of gemcitabine.
Collapse
Affiliation(s)
- Frédéric Gagnadoux
- Groupe de pneumologie Faculté de Médecine, INSERM, U618, IFR135, 37032 Tours, France.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Gagnadoux F, Le Pape A, Urban T, Montharu J, Vecellio L, Dubus JC, Leblond V, Diot P, Grimbert D, Racineux JL, Lemarié E. Safety of Pulmonary Administration of Gemcitabine in Rats. ACTA ACUST UNITED AC 2005; 18:198-206. [PMID: 15966774 DOI: 10.1089/jam.2005.18.198] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
The purpose of this research was to evaluate the safety of pulmonary administration of gemcitabine and to determine the maximum tolerated dose by weekly pulmonary administrations in an animal model. Five groups of eight Wistar rats received gemcitabine at doses of 2, 4, 6, or 8 mg/kg or the vehicle solution by endotracheal spray with scintigraphic imaging of lung deposition. In order to document the safety of digestive exposure, five groups of eight rats received gemcitabine at the same dosages or the vehicle solution by gavage. Nine weekly sessions were planned, and blood cell counts and histological examinations were performed in live animals at day 64. Scintigraphic imaging confirmed pulmonary deposition in 310 of 316 spray administrations (98%) with homogeneous pattern of deposition. The maximum tolerated dose of gemcitabine by pulmonary administration was 4 mg/kg. At this dosage, administered once a week for 9 consecutive weeks, there were no chemotherapy-related deaths and no clinical, histological, or hematological signs of toxicity except for a decrease in platelet and red blood cell counts, with no clinical significance. The toxicity of gemcitabine was higher via oral than lung delivery in terms of weight loss and white blood cell toxicity at dosages of 2, 4, and 6 mg/kg. Pulmonary administration of gemcitabine is safe in rats at a maximum tolerated dose of 4 mg/kg once a week for 9 weeks. At an equivalent dosage, the toxicity of gemcitabine is lower by lung than oral administration.
Collapse
Affiliation(s)
- Frédéric Gagnadoux
- Groupe de pneumologie, INSERM, U618, IFR135, Faculté de Médecine, Tours, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|